In Might 2025, the FDA named Prasad, an oncologist who beforehand criticized FDA management and COVID-19 mandates, because the director of its Middle for Biologics Analysis and Analysis.
The Washington Publish | The Washington Publish | Getty Pictures
Vinay Prasad, the U.S. Meals and Drug Administration’s chief medical and science officer, has left the well being regulator, the U.S. Division of Well being and Human Companies, which oversees the FDA, stated on Tuesday, confirming an earlier information report.
“Dr. Prasad didn’t wish to be a distraction to the good work of the FDA within the Trump administration and has determined to return to California and spend extra time together with his household,” an HHS spokesperson stated in an emailed assertion to Reuters.
“We thank him for his service and the numerous vital reforms he was in a position to obtain in his time at FDA.”
STAT Information first reported about Prasad’s departure, saying it got here after a variety of controversial choices by the FDA relating to a gene remedy drug for the remedy of Duchenne muscular dystrophy manufactured by Sarepta Therapeutics.
The company first halted shipments of the drug, referred to as Elevidys, after the deaths of some recipients however rescinded the suspension on Monday.
In June, STAT Information reported that Prasad was named because the well being regulator’s chief medical and science officer, citing an inner memo.
In Might, the FDA named Prasad, an oncologist who beforehand criticized FDA management and COVID-19 mandates, because the director of its Middle for Biologics Analysis and Analysis.